Published in Vaccine Weekly, September 6th, 2000
Campyvax is a vaccine for the prevention of gastroenteritis, diarrhea, and Traveler's Disease caused by Campylobacter, a common pathogenic bacterium. Under the terms of this CRADA, Antex will supply vaccine and research and development support to the Navy, and the Navy will fund and conduct clinical trials through Phase III. Antex holds all intellectual property and marketing rights to Campyvax.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly